Core Insights - China is transitioning from being a major exporter of raw materials to focusing on high-value-added pharmaceutical products, particularly Western medicine formulations [3][4]. Group 1: Export Performance - In 2025, China's export value of Western medicine formulations reached $8.841 billion, marking a year-on-year increase of 27.29% [3]. - The share of formulations in the total Western medicine export value reached a historical high of 15.85% [3]. - Formulations accounted for 7.94% of the overall pharmaceutical exports, indicating a significant upward trend [3]. Group 2: Growth Drivers - The export of formulations exhibited a "volume and price increase" trend, with export quantity rising by 17.71% and export price increasing by 8.01% year-on-year [3]. - Hormonal drugs were the primary driver of the substantial growth in formulation exports, with an export value of $3.153 billion, up 106% year-on-year [4]. - The export value of insulin analogs and GLP-1 peptide drugs reached $2.977 billion, showing a remarkable increase of 110.90% [5]. Group 3: Regional Market Insights - The European Union (excluding the UK) remained the largest market for Chinese formulations, with exports increasing by 70.4% year-on-year, a rise of approximately 10 percentage points compared to 2024 [3]. - Notable growth in exports to France (up 281.82%), Denmark (up 19.39%), and Italy (up 488.89%) was observed [3][5]. - In contrast, the share of exports to the U.S. decreased to 13.14%, down about 3.4 percentage points from 2024 due to tariff impacts [3]. Group 4: Market Dynamics - The surge in demand for insulin analogs and GLP-1 drugs is attributed to the rising incidence of metabolic diseases such as diabetes and obesity [5]. - Multinational companies are shifting their strategies from focusing solely on importing finished formulations to establishing local production capabilities in China, enhancing their global supply chain [5]. - Domestic companies are achieving technological breakthroughs and capacity releases in the insulin and GLP-1 sectors, actively participating in international markets and seeking registrations with regulatory bodies like the FDA and EMA [5].

Core Viewpoint - The impact of the U.S. tariffs on China continues to affect the pharmaceutical and medical device industries, with most medical consumables and devices not included in the exemption list, leading to increased tariff burdens [1][4][3]. Tariff Impact on Pharmaceuticals - Most pharmaceutical formulations, including various chemical drugs and vaccines, are exempt from the new 34% tariffs, maintaining a current tariff level of 20% [1]. - Specific drugs, such as those containing insulin and certain anti-malarial components, are excluded from tariffs, while medical devices like syringes will see tariffs rise from 120% to 154% [1][4]. Trade Statistics - In 2024, China's pharmaceutical exports to the U.S. are projected to reach $19.047 billion, with medical devices accounting for $11.758 billion and Western medicines for $6.425 billion [4]. - The U.S. remains China's largest export market for medical devices, comprising 24.1% of total exports [4]. Affected Sectors and Companies - The medical device sector, including syringes, gloves, and diagnostic equipment, is significantly impacted by the new tariffs, with companies like Canna, Kangdelai, and Wuzhou Medical being directly affected [5]. - Companies involved in the production of raw materials and pharmaceuticals, such as Hepalink and Hanyu Pharmaceutical, are also facing challenges due to the tariff changes [7][8]. Strategic Responses from Companies - Many pharmaceutical companies are adjusting their strategies to reduce reliance on the U.S. market by expanding into other regions like Europe and Southeast Asia [9][10]. - Companies like Mindray Medical and Hepalink have established local production facilities in the U.S. to mitigate tariff impacts and enhance compliance [10][11]. Internal Optimization Strategies - Some companies are focusing on improving internal operational efficiency and cost structures to withstand the uncertainties posed by the tariffs [12][13]. - For instance, Xianju Pharmaceutical is concentrating on production efficiency and cost reduction while shifting its export focus to the EU and Southeast Asia [12].